Mitochondrial Myopathies (MM)

Research

Research in mitochondrial disease has advanced significantly in recent years. Scientists are gaining a deeper understanding of how mitochondrial disorders develop, how they vary from person to person, and how they might be treated more precisely.

Genetic discoveries and improved diagnosis

Many mitochondrial diseases are now linked to specific genetic variants in either mitochondrial DNA (mtDNA) or nuclear DNA. Broader access to whole exome and whole genome sequencing has improved diagnostic accuracy and has helped identify new mitochondrial disease genes. These discoveries also support better family planning options and allow clinicians to match patients with trials based on their specific genetic subtype.

Disease models and mechanism research

Researchers have developed refined animal models, patient-derived cell models, and stem-cell–based systems to study mitochondrial dysfunction. These models help scientists understand how mitochondrial energy failure affects different tissues, how mtDNA mutations accumulate, and how mitochondria communicate with the rest of the cell.

Targeted and gene-based therapies

Therapeutic research is accelerating, with several approaches under active investigation:

• First approved therapy for TK2 Deficiency (TK2d): In 2025, the FDA approved KYGEVVI® (doxecitine + doxribtimine). It is the first treatment designed for a specific mitochondrial disease.
• Gene therapy and gene editing: Scientists are studying ways to replace faulty genes, repair them, or use RNA-based tools to help cells work better. These approaches target either nuclear genes or mitochondrial DNA.
• Enzyme or substrate replacement: For certain conditions, such as TK2d and MNGIE, researchers are looking at treatments that replace missing enzymes or reduce harmful substances that build up in the body.
• Mitochondrial DNA–focused approaches: New techniques aim to decrease damaging mtDNA variants or increase healthy ones using tools like base editors, targeted enzymes, and experimental methods to deliver genes directly to mitochondria.

Understanding mitochondrial behavior in cells

Beyond genetics, researchers are examining how mitochondria function as dynamic organelles—how they fuse, divide, and move within cells; how they interact with other cellular structures; and how these processes contribute to disease. This work may reveal new treatment pathways that do not require altering genes directly.

Clinical trials and future directions

Clinical trials are expanding in number and scope, evaluating targeted therapies, metabolic modulators, and mitochondrial support strategies. As researchers learn more about the underlying biology, treatment approaches are becoming more personalized, with the goal of addressing disease mechanisms rather than managing symptoms alone.

Additional reading

• Wen H et al. Mitochondrial diseases: from molecular mechanisms to therapeutic advances. Signal Transduct Target Ther. 2025 Jan 10;10(1):9. doi: 10.1038/s41392-024-02044-3.

Last reviewed May 2026.